INTRODUCTION AND OBJECTIVES:
In SPARTAN, pts with nmCRPC assessed by conventional imaging benefited from apalutamide (APA). PSMA-PET detects localized and metastatic PC with superior sensitivity to conventional imaging. We retrospectively characterized the extent of disease using PSMA-PET in SPARTANlike pts and compared the risk factors for M1 disease detected by PSMA-PET to those in SPARTAN.
METHODS: A total of 200 pts with nmCRPC at high risk of developing metastases (prostate-specific antigen doubling time [PSADT] 10 mo, or Gleason score ! 8) and no known extrapelvic metastases on prior conventional imaging were assessed with PSMA-PET. Detection rate on PSMA-PET, including local/pelvic and distant M1 disease, was determined. Association of baseline (BL) variables with M1 disease in the PSMA-PET cohort was assessed using univariate and multivariate analyses. SPARTAN pts were stratified according to risk factors for PSMA-PET-detected M1 disease and analyzed using Cox proportional-hazards models.
RESULTS: BL characteristics of PSMA-PET and SPARTAN pts were generally similar. PSMA-PET detected PC in 196/200 (98%) pts; 55% had local recurrence, 54% had pelvic nodes (N1), 55% had any extrapelvic distant metastatic disease despite negative conventional imaging; 24% were diagnosed with local recurrence only, 29% with oligometastatic (1-3 lesions) and 46% with polymetastatic disease. PSA ! 5.5 ng/mL, pN1 disease, and prior local therapy were significantly associated with M1 disease detected by PSMA-PET (Table) . All clinically relevant subgroups of SPARTAN pts, including pts with independent predictors of PSMA-PET-M1 disease, significantly benefited from APA (Table) .
CONCLUSIONS: PSMA-PET-positive CRPC pts were similar to those at high-risk of developing metastases in SPARTAN. APA showed significant benefit in all clinically relevant subgroups of SPARTAN pts, including pts with risk factors for distant metastases detected by PSMA-PET. Therefore, APA should be considered for pts negative by conventional imaging but positive by PSMA-PET (stage migration). The added value of PSMA-PET over PSADT in pts with high-risk nmCRPC should be explored in prospective studies. 
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PD17-10 QUANTITATIVE ANALYSIS BETWEEN APPARENT DIFFUSION COEFFICIENTS ON MRI AND CELLULARITY METRICS OF PROSTATE CANCER WITH WHOLE-MOUNT HISTOPATHOLOGY
Jie Gao*, Qing Zhang, Chengwei Zhang, Hongqian Guo, Nanjing, China, People's Republic of INTRODUCTION AND OBJECTIVES: Prostate cancer risk stratification at the time of diagnosis is necessary and cellularity metrics correlate with aggressiveness. We aimed to evaluate the relationship between apparent diffusion coefficients (ADCs) on MRI and cellularity metrics of prostate cancer (PCa) with whole-mount histopathology.
METHODS: 225 PCa patients with preoperative 3.0 T MRI and lesions more than 0.5cm on whole-mount specimens were enrolled. The mean, median and 10th percentile ADC values were derived with histogram from pathologic-matching MRI images. With digitized pathology, gland components including epithelium (nuclei and cytoplasm), stroma and glandular lumen were segmented by different settings with ImageScope, and cellularity metrics including nuclear fraction and nuclear-to-cytoplasmic ratio (NCR) were derived. Correlation of ADCs with cellularity metrics and gland components were evaluated with Pearson correlation coefficient r.
RESULTS: Total 256 lesions were identified and a representative pathologic segmentation illustration is shown in Fig 1. ADCs presented moderate correlation with NCR and nuclear fraction in both peripheral zone (PZ) and transition zone (TZ) (r[-0.370 to -0.403 and -0.471 to -0.528 for all lesions, P<0.001) (Fig 2, Table 1 ). Besides, of all lesions and PZ lesions, ADCs showed negative correlation with epithelial fraction and positive correlation with luminal fraction. Generally, epithelial fraction correlated most strongly with ADCs.
CONCLUSIONS: Quantitative ADC parameters moderately correlated with pathologic cellularity metrics including nuclear fraction and nuclear-to-cytoplasmic ratio of prostate cancer with whole-mount pathology. Vol. 201, No. 4S, Supplement, Friday, May 3, 2019 THE JOURNAL OF UROLOGY Ò e309
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